Search Results
Nov 25, 2025, 10:06 ET Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
models, IVT-8086 induces multiple antitumor effects, including potent reduction in tumor burden in primary and metastatic tumors, reduced expression of CD38 and PD-1 in tumor-infiltrating lymphocytes (TILs), inhibition of angiogenesis, and increased interferon gamma (IFNγ) in tumor-associated macrophages
More news about: Innova Therapeutics
Nov 25, 2025, 10:06 ET Innova Therapeutics bringt mit der Übernahme von Enci Therapeutics eine neuartige Krebsbehandlung voran
mehrere Antitumoreffekte aus, darunter eine starke Verringerung der Tumorlast in primären und metastasierenden Tumoren, eine verringerte Expression von CD38 und PD-1 in tumorinfiltrierenden Lymphozyten (TILs), eine Hemmung der Angiogenese und eine Erhöhung von Interferon gamma (IFNγ) in tumorassoziierten
More news about: Innova Therapeutics
Nov 25, 2025, 10:06 ET Innova Therapeutics fait progresser un nouveau traitement contre le cancer grâce à l'acquisition d'Enci Therapeutics
effets antitumoraux, y compris une réduction puissante de la charge tumorale dans les tumeurs primaires et métastatiques, une réduction de l'expression de CD38 et de PD-1 dans les lymphocytes infiltrant les tumeurs (TIL), une inhibition de l'angiogenèse et une augmentation de l'interféron gamma (IFNγ) dans
More news about: Innova Therapeutics
Nov 25, 2025, 10:06 ET Innova Therapeutics impulsará un nuevo tratamiento contra el cáncer con la adquisición de Enci Therapeutics
induce múltiples efectos antitumorales, incluyendo una potente reducción de la carga tumoral en tumores primarios y metastásicos, una menor expresión de CD38 y PD-1 en los linfocitos infiltrantes de tumores (TIL), la inhibición de la angiogénesis y un aumento del interferón gamma (IFNγ) en los macrófagos
More news about: Innova Therapeutics
Nov 25, 2025, 08:36 ET Menarini Group 宣佈將於第 67 屆美國血液學會年會暨展覽會 (67th American Society of Hematology Annual Meeting and Exposition) 發表 ELZONRIS® (tagraxofusp-erzs) 最新數據
的病人會出現皮膚病變。BPDCN 影響所有種族與地理區域的人群，全球年發病率約為每十萬人中有 0.4 至 0.5 例。雖然 BPDCN 會影響所有年齡層的男性和女性，但 75% 的病例發生於男性，發病年齡中位數為 60 至 70 歲。BPDCN 癌細胞的一項關鍵特徵是其高度表達一種名為 CD123 的蛋白質，該蛋白質可於細胞表面觀察到。這使得 CD123 成為重要的診斷標記物，同時也是精準療法直接打擊癌細胞的首要靶點。關於 ELZONRIS® (Tagraxofusp-erzs)美國適應症： ELZONRIS (tagraxofusp-erzs)
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 05:07 ET Menarini Group anuncia nuevos datos sobre ELZONRIS ® (tagraxofusp-erzs) que se presentarán en la 67ª Reunión y Exposición Anual de la Sociedad Americana de Hematología
60-70 años. Una característica clave de las células cancerosas BPDCN es su alta expresión de una proteína llamada CD123, que se puede observar en la superficie de las células. Esto hace que CD123 sea un marcador de diagnóstico crucial, así como un objetivo principal para las terapias de precisión para atacar
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 05:04 ET Menarini Group anuncia novos dados sobre ELZONRIS® (tagraxofusp-erzs) a serem apresentados na 67ª Reunião e Exposição Anual da Sociedade Americana de Hematologia
60-70 anos. Uma característica fundamental das células cancerígenas BPDCN é a alta expressão de uma proteína chamada CD123, que pode ser observada na superfície das células. Isso torna o CD123 um marcador de diagnóstico crucial, bem como um alvo principal para terapias de precisão atacarem o câncer diretamente.
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 04:53 ET Menarini Group anuncia nuevos datos sobre ELZONRIS® (tagraxofusp-erzs)
70 años. Una característica clave de las células cancerosas de BPDCN es su alta expresión de una proteína llamada CD123, que se puede observar en la superficie celular. Esto convierte a CD123 en un marcador diagnóstico crucial, así como en un objetivo principal para terapias de precisión que atacan directamente
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 04:44 ET 메나리니 그룹, 제67회 미국혈액학회 연례 학술대회에서 ELZONRIS®(tagraxofusp-erzs) 관련 신규 데이터 발표
CD123 양성 재발성 또는 불응성 급성 골수성 백혈병 치료를 위한 Tagraxofusp 및 저강도 화학 요법(Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123-Positive Relapsed or Refractory Acute Myeloid Leukemia) *
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 01:34 ET Halper Sadeh LLC Encourages JAMF, FRGE, SEE, MOVE Shareholders to Contact the Firm to Discuss Their Rights
to learn more about your legal rights and options.Sealed Air Corporation (NYSE: SEE)'s sale to funds affiliated with CD&R for $42.15 in cash per share. If you are a Sealed Air shareholder,
More news about: Halper Sadeh LLP
Nov 24, 2025, 16:52 ET Menarini Group gibt neue Daten zu ELZONRIS® (Tagraxofusp-erzs) bekannt, die auf der 67. Jahrestagung und Ausstellung der American Society of Hematology vorgestellt werden
60 und 70 Jahren liegt. Ein wesentliches Merkmal der BPDCN-Krebszellen ist die hohe Expression eines Proteins namens CD123, das auf der Oberfläche der Zellen zu finden ist. Dies macht CD123 zu einem wichtigen diagnostischen Marker und zu einem Hauptziel für präzise Therapien, die den Krebs direkt angreifen.Über
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 16:44 ET Menarini Group annonce de nouvelles données sur ELZONRIS® (tagraxofusp-erzs) qui seront présentées lors de la 67e réunion annuelle de l'American Society of Hematology
L'une des principales caractéristiques des cellules cancéreuses BPDCN est leur forte expression d'une protéine appelée CD123, qui peut être observée à la surface des cellules. Cela fait du CD123 un marqueur diagnostique crucial ainsi qu'une cible de choix pour les thérapies de précision visant à frapper directement
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 10:27 ET Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
age at onset of 60-70 years. A key characteristic of BPDCN cancer cells is their high expression of a protein called CD123, which can be observed on the surface of the cells. This makes CD123 a crucial diagnostic marker as well as a prime target for precision therapies to strike the cancer directly.About
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 10:20 ET Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
age at onset of 60-70 years. A key characteristic of BPDCN cancer cells is their high expression of a protein called CD123, which can be observed on the surface of the cells. This makes CD123 a crucial diagnostic marker as well as a prime target for precision therapies to strike the cancer directly.About
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
alone, and in combination with natalizumab resulted in robust CD34+ HSC mobilization.Motixafortide alone mobilized a median of 189 CD34+ cells/μl (range 77-690) to the peripheral blood (PB), with a median yield of 4.22x106 CD34+ cells/kg following a single blood volume collection, projecting
More news about: BioLineRx Ltd.
Nov 24, 2025, 06:03 ET Cell Therapy Market Size Set to More Than Double by 2030 -- North America Leads, While Asia-Pacific Emerges as the Fastest-Growing Region, Says Mordor Intelligence
CAR T-Cell Therapy Market: The CAR T-Cell Therapy Market is Segmented by Target Antigen (CD19, BCMA, CD22, GD2), Type (Abecma, Breyanzi), Cell Source (Autologous and Allogenic), Application (Leukemia, Lymphoma), End User (Hospitals, Cancer Care Treatment
More news about: Mordor Intelligence Private Limited
Nov 21, 2025, 17:40 ET Antlara Dental Introduces an AI assistant designed to help inform patients before their dental treatments
accommodation—for a seamless, stress-free experience.For more information, please contact Antlara DentalZumrutova, Sinanoğlu Cd. No. 53AMuratpasa/Antalya, Turkey.Phone: +44 7770 537 469Photo -
More news about: Antlara Dental
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy (ABSTRACT 25-3402) Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress
More news about: Hackensack Meridian John Theurer Cancer Center
Nov 21, 2025, 10:20 ET Prostate Cancer Drugs Market to Reach USD 28.10 Billion by 2033 | According to DataM Intelligence
(USA)Though historically focused on other indications, FibroGen licensed an antibody-drug conjugate (ADC) FG-3246 targeting CD46 for mCRPC.Early Phase 2 results (PSA50 response ~36% in heavily-pretreated mCRPC) indicate potential in a tough indication.The shift
More news about: DataM Intelligence 4 Market Research LLP
Nov 21, 2025, 08:49 ET CD Rate Trends in November 2025 - CD Valet's CD APY Checkpoint Reveals Slight Rate Decline Across Most Terms
difference in yields."About CD ValetCD Valet is a digital marketplace that connects consumers with top CD rates from banks and credit unions nationwide and enables financial institutions to efficiently and cost-effectively attract retail deposits. With CD Valet, banks and credit unions
More news about: CD Valet
Nov 21, 2025, 07:37 ET Les données de PMB-CT01 BAFFR-CAR T de PeproMene Bio ont été sélectionnées pour deux présentations orales lors de la 67e réunion annuelle de l'ASH 2025.
antérieur dirigé contre le CD19 a échoué ou qui présentaient une maladie CD19-négative. Les résultats intermédiaires des études de phase 1 à doses croissantes (NCT04690595, NCT05370430) confirment que BAFF-R est une cible différenciée conçue pour surmonter l'échappement à l'antigène CD19 tout en maintenant
More news about: PeproMene Bio, Inc.
Nov 21, 2025, 06:42 ET Weekly Recap: 10 Finance Press Releases You Need to See
Sealed Air to be Acquired by CD&R for $10.3 Billion"This transaction delivers significant and derisked value to Sealed Air stockholders while accelerating our ongoing transformation. CD&R's partnership will enhance our ability to invest in growing
More news about: PR Newswire
Nov 21, 2025, 06:02 ET 14 Press Releases You Need to See This Week
Sealed Air to be Acquired by CD&R for $10.3 Billion"This transaction delivers significant and derisked value to Sealed Air stockholders while accelerating our ongoing transformation. CD&R's partnership will enhance our ability to invest in growing
More news about: PR Newswire
Nov 20, 2025, 19:08 ET 페프로민 바이오, BAFFR-CAR T 'PMB-CT01' 데이터, 2025년 ASH 제67차 연례학회 구두 발표 2건 선정
급성 림프구성 백혈병(B-ALL) 및 r/r B세포 비호지킨 림프종(B-NHL) 환자를 대상으로 한 PMB-CT01의 초기 안전성 및 유효성 프로파일을 제시한다. 여기에는 기존 CD19 표적 치료에 실패했거나 CD19 음성 질환을 가진 환자도 포함된다. 임상 1상 단계적 용량증량 연구(NCT04690595, NCT05370430)의 중간 결과는 BAFF-R이 CD19 항원 소실을 극복하면서 내구성을 유지하고 독성이 낮은 차별화된 표적임을 시사한다.r/r B-NHL안전성:PMB-CT01은
More news about: PeproMene Bio, Inc.
Nov 20, 2025, 16:25 ET Daten zu PMB-CT01 BAFFR-CAR T von PeproMene Bio für zwei mündliche Präsentationen auf der 67. Jahrestagung 2025 von ASH ausgewählt
Patienten, bei denen eine vorherige CD19-gerichtete Therapie versagt hat oder die eine CD19-negative Erkrankung aufweisen. Die Zwischenergebnisse der Phase-1-Dosis-Eskalationsstudien (NCT04690595, NCT05370430) unterstützen BAFF-R als differenziertes Zielmolekül, das die CD19-Antigen-Flucht überwinden und
More news about: PeproMene Bio, Inc.